Skip to main content
SpringerLink
Log in

Additional Transporter Characterization May Lead to New Pharmaceutical Opportunities

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. A. Silverman. Multidrug-resistance Transporters. In G. L. Amidon and W. Sadee (eds). Membrane Transporters as Drug Targets, Vol. 12, Pharmaceutical Biotechnology, Kluwer Academic/Plenum Publishers, New York, 1999, pp. 353-386.

    Google Scholar 

  2. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan and M. M. Gottesman. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398 (1999).

    Google Scholar 

  3. I. C. J. v. d. Sandt, P. J. Gaillard, H. H. Voorwinden, A. G. d. Boer and D. D. Breimer, P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain-barrier. Pharm. Res. 18:587-592 (2001).

    Google Scholar 

  4. E.-j. Wang, C. N. Casciano, R. P. Clement and W. W. Johnson. Inhibition of p-glycoprotein transport function by grapefruit juice psoralen. Pharm. Res. 18:432-438 (2001).

    Google Scholar 

  5. E.-j. Wang, C. N. Casciano, R. P. Clement and W. W. Johnson. HMG-CoA reductase Inhibitors (statins) characterized as direct inhibitors of p-glycoprotein. Pharm. Res. 18:800-806 (2001).

    Google Scholar 

  6. J. Gao, O. Murase, R. L. Schowen, J. Aube and R. T. Borchardt. A functional assay for quantitation of the apparent affinities of ligands of p-glycoprotein in caco-2 cells. Pharm. Res. 18:171-176 (2001).

    Google Scholar 

  7. S. Cisternino, C. Rousselle, C. Dagenais and J.-M. Scherrmann. Screening of multidrug-resistance sensitive drugs in situ brain perfusion in p-glycoprotein-deficient mice. Pharm. Res. 18:183-190 (2001).

    Google Scholar 

  8. A. B. Shapiro and V. Ling. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250:130-137 (1997).

    Google Scholar 

  9. S. Dey, M. Ramachandra, I. Pastan, M. M. Gottesman and S. V. Ambudkar. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl Acad. Sci. USA 94:10594-10599 (1997).

    Google Scholar 

  10. A. B. Shapiro, K. Fox, P. Lam and V. Ling. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 259:841-850 (1999).

    Google Scholar 

  11. Y.-H. Han, Y. Kato, M. Haramura, M. Ohta, H. Matsuoka and Y. Sugiyama. Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canicular multispecific organic anion transporter (cMOAT/MRP2). Pharm. Res. 18:579-586 (2001).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Small Molecular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080

    Olafus S. Gudmundsson

Authors
  1. Olafus S. Gudmundsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gudmundsson, O.S. Additional Transporter Characterization May Lead to New Pharmaceutical Opportunities. Pharm Res 18, 1481–1482 (2001). https://doi.org/10.1023/A:1013014709104

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013014709104

Keywords

Search

Navigation